Condition: Malignant Solid Tumors · Primary Brain Tumor · Melanoma · Sponsor: N.N. Petrov National Medical Research Center of Oncology
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
This description comes directly from the study's public registry record.
Aleksei Novik, MD, PhD · +78124399505 · alexey.viktorovich.novik@gmail.com
Tatiana Nekhaeva, MD, PhD · +78124399514 · nehaevat151274@mail.ru
Always discuss trial participation with your own doctor first.
| N.N. Petrov NMRC of Oncology, Oncoimmunology dep. | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05539677